Search results
Results From The WOW.Com Content Network
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Larger doses of radiation are used in modern chemoradiotherapy protocols versus the original Nigro protocol radiotherapy dose. In the Nigro protocol, the patient receives 30 Gy (3000 rads) of radiation over a three-week period, as well as continuous administration of fluorouracil for the first four days and on days 20–31, with bolus mitomycin ...
FOLFIRI is a chemotherapy regimen for treatment of colorectal cancer.It is made up of the following drugs: [1] FOL – folinic acid (), a vitamin B derivative with multiple applications, which in this context decreases the cytotoxicity of 5-fluorouracil;
Premedication is using medication before some other therapy (usually surgery or chemotherapy) to prepare for that forthcoming therapy. Typical examples include premedicating with a sedative or analgesic before surgery; using prophylactic (preventive) antibiotics before surgery; and using antiemetics or antihistamines before chemotherapy.
%PDF-1.4 %âãÏÓ 6 0 obj > endobj xref 6 120 0000000016 00000 n 0000003048 00000 n 0000003161 00000 n 0000003893 00000 n 0000004342 00000 n 0000004557 00000 n 0000004733 00000 n 0000005165 00000 n 0000005587 00000 n 0000005635 00000 n 0000006853 00000 n 0000007332 00000 n 0000008190 00000 n 0000008584 00000 n 0000009570 00000 n 0000010489 00000 n 0000011402 00000 n 0000011640 00000 n ...
Cetuximab (trade name: Erbitux ) is a recombinant chimeric monoclonal antibody designed to treat metastatic colorectal cancer and head and neck cancer. [14] In numerous cancers, the epidermal growth factor receptor (EGFR) is often inappropriately activated and overexpressed in cancer cells, leading to uncontrolled cell growth. [ 15 ]
The dose schedule given every two weeks is as follows: [5] Day 1–2: Oxaliplatin 100 mg/m 2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m 2 (or levoleucovorin 200 mg/m 2) IV infusion, followed by 5-FU 400 mg/m 2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m 2 for first two cycles, and may be increased to 3000 mg/m 2 if tolerated by ...
Afucosylated antibodies are intensely used in the field of advanced medicine, also due to their high ADCC (antibody-dependent cellular cytotoxicity). This makes them effective in binding to specific targets while minimizing damage to surrounding tissue.